RESUMEN
Objective@#The objective of this study was to present the real-world patients’ portrait, and the results of niraparib treatment in China. @*Methods@#This study included 142 patients treated with niraparib from 8 hospitals in China between December 2018 and September 2021. Patients’ characteristics were summarized. The efficacy and safety in first-line maintenance (1L-M), platinum-sensitive recurrence maintenance (PSR-M), and treatment for ovarian cancer were evaluated. Survival outcomes and the factors influencing progression-free survival (PFS) were estimated. @*Results@#The 93 patients received Niraparib as 1L-M, 31 as PSR-M and 18 as salvage. BRCA status was wild type or unknown in 87.3% of patients. With a median follow-up time of 8.7 months, the median PFS (mPFS) for 1L-M has not yet been reached, and the mPFS for PSR-M and salvage therapy was 10.5 and 5.7 months, respectively. Responses to last chemotherapy and cancer antigen 125 value before taking niraparib were 2 important factors affecting PFS among 1L and PSR patients. The 12.7% (18/142) of patients experienced grade ≥3 hematologic adverse events and 23.2% experienced dose adjustment. It was noteworthy that when the interval of chemotherapy and niraparib <21 days, the incidence of grade ≥3 adverse events increased significantly (p=0.0355). @*Conclusion@#Generally, niraparib was effective and well tolerated, which was consistent with the results of prospective trials. However, in real world, it was more inclined to use niraparib in late-line treatment without genetic testing.
RESUMEN
Objective To investigate the feasibility of methotrexate incision and different methods of administration combined with hysteroscopic surgery for cesarean scarpregnancy (CSP).Methods Retrospective analysis of 106 patients with CSP in our hospital from January 2001 to December 2015 were.The patients were divided into two groups, group A of 66 cases: methotrexate ( MTX) incision and systemic administration combined with hysteroscopic surgery group B of 40 cases: methotrexate combined with hysteroscopy surgery.The operation time, intraoperative blood loss, preoperative hospital stay, the time of blood HCG decreased to normal, the total amount of MTX and the abnormal rate of liver function were compared between the two groups, and the factors affecting the prognosis of CSP were analyzed.Results The preoperative hospitalization time and abnormal liver function of the two groups were compared, the difference was statistically significant(P3 mm, before treatment, blood HCG≤20000IU/L, GS≤40 mm CSP more secure.
RESUMEN
Objective To evaluate the administration of dinoprostone suppositories in induced labor for full-term pregnancy women with hypertensive disorders.Methods One hundred and nine full-term pregnant women admitted in Jiaxing Maternal and Child Health Care Hospital from February 2010 to December 2011 were included in the study.The subjects included 43 cases with pregnant hypertension (group A),36 cases with mild preeclampsia (group B),30 cases with severe preeclampsia (group C),and 30 full-term normal puerpera were also included (group D).Dinoprostone suppositories were placed in the vagina for induction.The cesarean delivery rate and perinatal prognosis were compared among the four groups.Results The cesarean delivery rate in group C was higher than other 3 groups; there was no significant difference among groups A,B and D.The rates of fetal distress and postpartum hemorrhage in group C were higher than those in other 3 groups; there were no significant differences in rates of fetal distress and postpartum hemorrhage among group A,B and D,while there was no difference in rate of neonatal asphyxia among all groups.Conclusion Dinoprostone is effective and safe in inducing labor for full-term pregnancy women with hypertensive disorders.